BSECompany UpdateResults3d ago
Sandu Pharmaceuticals Ltd
Newspaper publication in respect of Unaudited Financials for the Q and Half Year ended 30th September 2026
Sandu Pharmaceuticals Ltd has published unaudited financial results for Q ended 30th September 2026 in newspapers 'Navprabha' and 'Navhind Times' as per Regulation 30 of SEBI (LODR) 2015.
BSECompany UpdateResults5d ago
Sandu Pharmaceuticals Ltd
statement of deviation and variation of funds for q ended 30th sept 2026
Sandu Pharmaceuticals Ltd has filed a statement of deviation and variation of funds for the quarter ended 30th September 2026, related to the preferential issue of equity shares (private placement) raised on 28th February 2022. The company has utilized the proceeds for the revamping of the capital, developing marketing infrastructure, and purchasing new/ additional plant and machinery.
BSEResult▲ PositiveResults5d ago
Sandu Pharmaceuticals Ltd
Results for Q and half year ended 30th sept 2026
Sandu Pharmaceuticals Ltd announced its unaudited financial results for the quarter and half year ended 30th September 2026, with a profit before exceptional items and tax of ₹8591, a net profit for the period of ₹853, and a total comprehensive income for the period of ₹9223. The company's standalone balance sheet as at 30th September 2026 showed total assets of ₹5717.57 lakhs and total liabilities of ₹5717.67 lakhs.
BSEBoard MeetingResults5d ago
Sandu Pharmaceuticals Ltd
Outcome of the Board Meeting dated 14th November 2026
Sandu Pharmaceuticals Ltd announced the outcome of its board meeting held on November 14, 2026, where it approved the unaudited financial results for the quarter and half-year ended September 30, 2026. The results showed a profit before tax of ₹12197, and the company's board of directors took on record the unaudited financial results and the limited review report issued by the statutory auditors.
BSECompany Update9 Nov 2026
Sandu Pharmaceuticals Ltd
Newspaper Publication for opening of special widow for re-lodgment of transfer requests for physical shares
Sandu Pharmaceuticals Ltd has published a newspaper advertisement for the opening of a special window for re-lodgment of transfer requests for physical shares, as per SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/1/3750/2026.
BSEBoard MeetingResults4 Nov 2026
Sandu Pharmaceuticals Ltd
Sandu Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 ,inter alia, to consider and approve Approval of Unaudited Financials for Q and half year ended 30th September 2026
Sandu Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 14/11/2026 to consider and approve the Unaudited Financials for Q and half year ended 30th September 2026.
BSECompany UpdateMgmt Change9 Oct 2026
Sandu Pharmaceuticals Ltd
Intimation about change in name of Director from Dr Neeti Madan Kapre to Dr Neeti Gupta
Sandu Pharmaceuticals Ltd has informed the exchange about a change in the name of its non-executive independent director, Dr. Neeti Madan Kapre, to Dr. Neeti Gupta, due to her marriage, with no change in designation, directorship, or DIN.
BSECompany Update8 Oct 2026
Sandu Pharmaceuticals Ltd
compliance certificate under Reg 74(5) of SEBI(DP) Regulation for Q ended 30th September 2026
Sandu Pharmaceuticals Ltd has submitted a compliance certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018, confirming the dematerialization of securities for the quarter ended 30th September 2026.
BSECompany UpdateRegulatory30 Sept 2026
Sandu Pharmaceuticals Ltd
Intimation to the holders of Physical Securities to furnish PAN and KYC details
Sandu Pharmaceuticals Ltd has issued an intimation to the holders of physical securities to furnish PAN and KYC details as per SEBI Master Circular dated June 23, 2025. The company has provided forms and details on its website for the updation of KYC details.
BSEInsider Trading / SASTResults22 Sept 2026
Sandu Pharmaceuticals Ltd
Intimation about closure of trading window for Quarter ended 30th September 2026
Sandu Pharmaceuticals Ltd has announced the closure of its trading window for the quarter ended 30th September 2026, effective from 15th October 2026, until 48 hours after the declaration of the financial results. The trading window closure is in accordance with the 'Code of Conduct for Prevention of Insider Trading' and SEBI regulations.
BSECompany UpdateMgmt Change12 Sept 2026
Sandu Pharmaceuticals Ltd
1. Redesignation of shri Balram Viswanathan (DIN :10245195)as Chairman and Managing Director of the company.
2.Appointment of Dr Smt Neeti Kapre (DIN:06801264)as Non Executive Independent Director
Sandu Pharmaceuticals Ltd has announced the redesignation of Balram Viswanathan as Chairman and Managing Director for 3 years and the appointment of Neeti Kapre as Non-Executive Independent Director for 5 years, both effective from July 11, 2026.
BSECompany Update4 Sept 2026
Sandu Pharmaceuticals Ltd
Newspaper Publication opening of special window for re-lodgement of transfer request for physical shares
Sandu Pharmaceuticals Ltd has published a newspaper advertisement for the opening of a special window for re-lodgment of transfer requests for physical shares, as per SEBI Circular No.HO/38/13/11(2)2026-MIRSD-POD/1/3750/2026 dated January 30, 2026.
BSECompany UpdateResults20 Aug 2026
Sandu Pharmaceuticals Ltd
Newspaper Advertisement intimating shareholders about Notice of Annual General Meeting and Evoting
Sandu Pharmaceuticals Ltd has announced the Notice of Annual General Meeting and E-voting through a newspaper advertisement, as per Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
BSECompany UpdateResults19 Aug 2026
Sandu Pharmaceuticals Ltd
Letters to shareholders on annual report weblink whose email ids are not registered with the company/RTA
Sandu Pharmaceuticals Ltd announced that the 41st Annual General Meeting (AGM) of the company will be held on September 11, 2026, through video conferencing. The company is sending a letter to shareholders who have not registered their email address with the Depository Participants (DP) or the Company/Registrar & Transfer Agent (RTA), providing the web-link to the Annual Report for FY 2026-27.
BSEOthers▲ PositiveResults19 Aug 2026
Sandu Pharmaceuticals Ltd
41st Annual Report of Sandu Pharmaceuticals Limited
Sandu Pharmaceuticals Ltd has released its 41st Annual Report for the financial year 2025-26, highlighting a 23.187% increase in net profit despite market challenges, with a revenue of ₹6,993.45 lakhs. The company has strengthened its business foundations, enhanced operational efficiencies, and continued to invest in growth initiatives.
BSEAGM/EGMResults19 Aug 2026
Sandu Pharmaceuticals Ltd
Intimation about Annual General Meeting
Sandu Pharmaceuticals Ltd has announced the 41st Annual General Meeting (AGM) to be held on September 11, 2026, through video conferencing or other audio-visual means. The meeting will consider and adopt the audited standalone financial statements for the financial year ended March 31, 2026, and reappoint the statutory auditors, M/s. Dave & Dave, for a term of five years. The company will also consider a dividend of 10% on paid-up capital.
BSECompany UpdateResults14 Aug 2026
Sandu Pharmaceuticals Ltd
Newspaper Advertisement Pre despatch of Annual Report intimation to Shareholders
Sandu Pharmaceuticals Ltd has announced the pre-despatch of its annual report and the 41st Annual General Meeting through electronic mode (Video Conference and other Audio visual means). The meeting will be held on September 11, 2026. The company has also announced a change of name for its promoter, MIHIR MOHAN KORGAONKAR, to MIHIR MOHAN.
BSECompany UpdateResults13 Aug 2026
Sandu Pharmaceuticals Ltd
Newspaper Publication Unaudited Financials for Q ended 30th June 2026
Sandu Pharmaceuticals Ltd has published unaudited financial results for the quarter ended 30th June 2026 in the newspapers 'Navprabha' and 'Navhind Times'.
BSECompany UpdateRelated Party11 Aug 2026
Sandu Pharmaceuticals Ltd
approval of material related party transactions subject to approval of shareholder
Sandu Pharmaceuticals Ltd has approved the unaudited standalone financial results for the quarter ended June 30, 2026, and recommended the proposal for obtaining approval of the members at the ensuing Annual General Meeting for the continuation of material related party transactions with M/s. Sandu Brothers Private Limited.
BSECompany Update11 Aug 2026
Sandu Pharmaceuticals Ltd
statement of deviation and utlisation of funds for q ended 30.06.2026
Sandu Pharmaceuticals Ltd has filed a statement of deviation and utilisation of funds for the quarter ended 30.06.2026, stating that the company has not deviated from the original objects for which the funds were raised through preferential issues in 2021 and 2022.